Paliperidone LAI Shows Lowest Risk of Schizophrenia Relapse & Treatment Failure

With a 0.66 adjusted hazard ratio for relapse, paliperidone 3-month LAI outperforms oral olanzapine, significantly lowering schizophrenia relapse risk in the largest real-world comparison of antipsychotics.